TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases

Cell Reports

Volumn 2, Issue 3, 2012, Pages 568-579

  Hsu, Chih Hung ^a,j,l   Peng, Kai Lin ^a,b,j   Kang, Ming Lun ^a,k   Chen, Yi Ren ^c,k   Yang, Yu Chih ^c   Tsai, Chin Hsien ^c,d   Chu, Chi Shen ^a,e   Jeng, Yung Ming ^d   Chen, Yen Ting ^a,e   Lin, Feng Mao ^f   Huang, Hsien Da ^f   Lu, Yun Yuh ^a   Teng, Yu Ching ^a,b   Lin, Shinn Tsuen ^g   Lin, Ruo Kai ^a   Tang, Fan Mei ^h   Lee, Sung Bau ^a   Hsu, Huan Ming ⁱ   Yu, Jyh Cherng ⁱ   Hsiao, Pei Wen ^c   Juan, Li Jung ^a,b,e   more..

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^g R and D department   (Taiwan)

^h INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

ⁱ TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIOXYGENASE; DNA; PROTEIN TET1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; DIOXYGENASES; DNA METHYLATION; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR SUPPRESSOR PROTEINS;

CITRUS MAXIMA;

EID: 84866908544     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.08.030     Document Type: Article

References (47)

1. An W., Kim J., Roeder R.G. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 2004, 117:735-748.
2. Anania M.C., Sensi M., Radaelli E., Miranda C., Vizioli M.G., Pagliardini S., Favini E., Cleris L., Supino R., Formelli F., et al. TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene 2011, 30:3011-3023.
3. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., Baylin S.B., Graff J.R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999, 59:798-802.
4. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20:161-168.
5. Cameron E.E., Bachman K.E., Myöhänen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21:103-107.
6. Chernov A.V., Sounni N.E., Remacle A.G., Strongin A.Y. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J. Biol. Chem. 2009, 284:12727-12734.
7. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 2008, 40:1362-1378.
8. Clark I.M., Young D.A., Rowan A.D. Matrix metalloproteinase protocols 2010, Humana Press, New York, N.Y. Second Edition.
9. Dawlaty M.M., Ganz K., Powell B.E., Hu Y.C., Markoulaki S., Cheng A.W., Gao Q., Kim J., Choi S.W., Page D.C., Jaenisch R. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9:166-175.
10. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
11. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
12. Ficz G., Branco M.R., Seisenberger S., Santos F., Krueger F., Hore T.A., Marques C.J., Andrews S., Reik W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473:398-402.
13. Frauer C., Rottach A., Meilinger D., Bultmann S., Fellinger K., Hasenöder S., Wang M., Qin W., Söding J., Spada F., Leonhardt H. Different binding properties and function of CXXC zinc finger domains in Dnmt1 and Tet1. PLoS ONE 2011, 6:e16627.
14. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
15. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
16. Haffner M.C., Chaux A., Meeker A.K., Esopi D., Gerber J., Pellakuru L.G., Toubaji A., Argani P., Iacobuzio-Donahue C., Nelson W.G., et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2:627-637.
17. He Y.-F., Li B.-Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
18. Hojilla C.V., Wood G.A., Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008, 10:205.
19. Hsu C.-H., Chang M.D.T., Tai K.-Y., Yang Y.-T., Wang P.-S., Chen C.-J., Wang Y.-H., Lee S.-C., Wu C.-W., Juan L.-J. HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J. 2004, 23:2269-2280.
20. Hu X., Beeton C. Detection of functional matrix metalloproteinases by zymography. J. Vis. Exp. 2010, 45:e2445.
21. Hua H., Li M., Luo T., Yin Y., Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell. Mol. Life Sci. 2011, 68:3853-3868.
22. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
23. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
24. Jin S.G., Jiang Y., Qiu R., Rauch T.A., Wang Y., Schackert G., Krex D., Lu Q., Pfeifer G.P. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71:7360-7365.
25. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
26. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., An J., Lamperti E.D., Koh K.P., Ganetzky R., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
27. Kudo Y., Tateishi K., Yamamoto K., Yamamoto S., Asaoka Y., Ijichi H., Nagae G., Yoshida H., Aburatani H., Koike K. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012, 103:670-676.
28. Kulis M., Esteller M. DNA Methylation and Cancer. Advances in Genetics 2010, 27-56. Academic Press. H. Zdenko, U. Toshikazu (Eds.).
29. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
30. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12:233.
31. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002, 62:4075-4080.
32. Smith E., De Young N.J., Tian Z.Q., Caruso M., Ruszkiewicz A.R., Liu J.F., Jamieson G.G., Drew P.A. Methylation of TIMP3 in esophageal squamous cell carcinoma. World J. Gastroenterol. 2008, 14:203-210.
33. Song C.-X., Szulwach K.E., Fu Y., Dai Q., Yi C., Li X., Li Y., Chen C.-H., Zhang W., Jian X., et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 2011, 29:68-72.
34. Taberlay P.C., Jones P.A. DNA methylation and cancer. Prog. Drug Res. 2011, 67:1-23.
35. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
36. Tsai C.-H., Lin F.-M., Yang Y.-C., Lee M.-T., Cha T.-L., Wu G.-J., Hsieh S.-C., Hsiao P.-W. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin. Cancer Res. 2009, 15:5435-5444.
37. Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A.C., Rappsilber J., Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473:343-348.
38. Wu S.C., Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 2010, 11:607-620.
39. Wu H., Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011, 25:2436-2452.
40. Wu H., Zhang Y. Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells. Cell Cycle 2011, 10:2428-2436.
41. Wu H., D'Alessio A.C., Ito S., Xia K., Wang Z., Cui K., Zhao K., Sun Y.E., Zhang Y. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011, 473:389-393.
42. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.-H., Ito S., Yang C., Wang P., Xiao M.-T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
43. Xu Y., Wu F., Tan L., Kong L., Xiong L., Deng J., Barbera A.J., Zheng L., Zhang H., Huang S., et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 2011, 42:451-464.
44. Yang H., Liu Y., Bai F., Zhang J.Y., Ma S.H., Liu J., Xu Z.D., Zhu H.G., Ling Z.Q., Ye D., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2012, Published online March 5, 2012. 10.1038/onc.2012.67.
45. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.
46. Zeng Z.-S., Cohen A.M., Guillem J.G. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999, 20:749-755.
47. Zhang H., Zhang X., Clark E., Mulcahey M., Huang S., Shi Y.G. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res. 2010, 20:1390-1393.